Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice

Gene Therapy volume 12, pages 281–287 (2005)Cite this article

Abstract

Tuberculosis (TB) remains a threat for public health, killing around 3 million people a year. Despite the fact that most cases can be cured with antibiotics, the treatment is long and patients relapse if chemotherapy is not continued for at least 6 months. Thus, a better characterization of the working principles of the immune system in TB and identification of new immunotherapeutic products for the development of shorter regimens of treatment are essential to achieve an effective management of this disease. In the present work, we demonstrate that immunotherapy with a plasmid DNA encoding the Mycobacterium leprae 65 kDa heat-shock protein (hsp65) in order to boost the efficiency of the immune system, is a valuable adjunct to antibacterial chemotherapy to shorten the duration of treatment, improve the treatment of latent TB infection and be effective against multidrug-resistant bacilli (MDR-TB). We also showed that the use of DNA-hsp65 alone or in combination with other drugs influence the pathway of the immune response or other types of inflammatory responses and should augment our ability to alter the course of immune response/inflammation as needed, evidencing an important target for immunization or drug intervention.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Kochi A . Global challenge of tuberculosis. Lancet 1994; 44: 608–609.

    Google Scholar 

  2. Young DB, Duncan K . Prospects for new interventions in the treatment and prevention of mycobacterial disease. Annu Rev Microbiol 1995; 49: 641–673.

    Article  CAS  PubMed  Google Scholar 

  3. Bass Jr JB et al. Treatment of tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149: 1359–1374.

    Article  PubMed  Google Scholar 

  4. Mitchison DA . The action of antituberculosis drugs in short-course chemotherapy of M. tuberculosis. Tubercle 1985; 66: 219.

    Article  CAS  PubMed  Google Scholar 

  5. Manabe YC, Bishai WR . Latent Mycobacterium tuberculosis – persistence, patience, and winning by waiting. Nat Med 2000; 6: 1327–1329.

    Article  CAS  PubMed  Google Scholar 

  6. Kaufmann SHE . Is the development of a new tuberculosis vaccine possible? Nat Med 2000; 6: 955–960.

    Article  CAS  PubMed  Google Scholar 

  7. Lowrie DB, Tascon RE, Colston MJ, Silva CL . Towards a DNA vaccine against tuberculosis. Vaccine 1994; 12: 1537–1540.

    Article  CAS  PubMed  Google Scholar 

  8. Tascon RE et al. Vaccination against tuberculosis by DNA injection. Nat Med 1996; 2: 888–892.

    Article  CAS  PubMed  Google Scholar 

  9. Bonato VLD et al. Identification and characterization of protective T cells in hsp65 DNA-vaccinated and Mycobacterium tuberculosis-infected mice. Infect Immun 1998; 66: 169–175.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Silva CL, Lowrie DB . Identification and characterization of murine cytotoxic T cells that kill Mycobacterium tuberculosis. Infec Immun 2000; 68: 3269–3274.

    Article  CAS  Google Scholar 

  11. Lowrie DB et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999; 400: 269–271.

    Article  CAS  PubMed  Google Scholar 

  12. Lowrie DB, Silva CL . Enhancement of immunocompetence in tuberculosis by DNA vaccination. Vaccine 2000; 18: 1712–1716.

    Article  CAS  PubMed  Google Scholar 

  13. Ha SJ et al. Therapeutic effect of DNA vaccines combined with chemotherapy in a latent infection model after aerosol infection of mice with Mycobacterium tuberculosis. Gene Therapy 2003; 10: 1592–1599.

    Article  CAS  PubMed  Google Scholar 

  14. Lai WC et al. Therapeutic effect of DNA immunization of genetically susceptible mice infected with virulent Mycoplasma pulmonis. J Immunol 1997; 158: 2513–2516.

    CAS  PubMed  Google Scholar 

  15. Collins HL, Kaufmann SHE . The many faces of host responses to tuberculosis. Immunology 2001; 103: 1–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Flynn JL, Ernst JD . Immune responses in tuberculosis. Curr Opin Immunol 2000; 12: 432–438.

    Article  CAS  PubMed  Google Scholar 

  17. Silva CL et al. Characterization of the memory/activated T cells that mediate the long-lived host response against tuberculosis after bacillus Calmette–Guérin or DNA vaccination. Immunology 1999; 97: 573–581.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Yang ZY et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004; 428: 861–864.

    Google Scholar 

  19. Lima KM et al. Comparison of different delivery systems of vaccinations for the induction of protection against tuberculosis in mice. Vaccine 2001; 19: 3518–3525.

    Article  CAS  PubMed  Google Scholar 

  20. Lima KM et al. Efficacy of DNA-hsp65 vaccination for tuberculosis varies with method of DNA introduction in vivo. Vaccine 2003; 22: 49–56.

    Article  CAS  PubMed  Google Scholar 

  21. De Wit D, Wootton M, Dhillon J, Mitchison DA . The bacterial DNA content of mouse organs in the Cornell model of dormant tuberculosis. Tubercle Lung Dis 1995; 76: 555–562.

    Article  CAS  Google Scholar 

  22. Flynn JL et al. An essential role for interferon γ in resistance to Mycobacterium tuberculosis. J Exp Med 1993; 178: 2249–2254.

    Article  CAS  PubMed  Google Scholar 

  23. Orme IM, Cooper AM . Cytokine/chemokine cascades in immunity to tuberculosis. Immunol Today 1999; 20: 307–312.

    Article  CAS  PubMed  Google Scholar 

  24. Butcher EC, Picker LJ . Lymphocyte homing and homeostasis. Science 1996; 272: 60–66.

    Article  CAS  PubMed  Google Scholar 

  25. Mackay CR . Homing of naive, memory and effector lymphocytes. Curr Opin Immunol 1993; 5: 423–427.

    Article  CAS  PubMed  Google Scholar 

  26. Trinchieri G . Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13: 251–276.

    Article  CAS  PubMed  Google Scholar 

  27. Sallusto F et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708–712.

    Article  CAS  PubMed  Google Scholar 

  28. Abbas AK, Murphy KM, Sher A . Functional diversity of helper T lymphocytes. Nature 1996; 383: 787–793.

    Article  CAS  PubMed  Google Scholar 

  29. Lazanvecchia A . Identifying strategies for immune intervention. Science 1993; 260: 937–944.

    Article  Google Scholar 

  30. Thomson J . New TB vaccines to be tested. Nat Med 2001; 7: 1263.

    Article  CAS  PubMed  Google Scholar 

  31. Enserink M . Driving a stake into resurgent TB. Science 2001; 293: 234–235.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Izaíra T Brandão for technical assistance. This study was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), Instituto do Milênio REDE TB and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).

Author information

Authors and Affiliations

  1. REDE-TB, Departamento de Bioquímica e Imunologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil

    C L Silva, V L D Bonato, A A M Coelho-Castelo, A O De Souza, S A Santos & K M Lima

  2. Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil

    L H Faccioli

  3. Nanocore Biotecnologia LTDA, Brazil

    J M Rodrigues Jr

Authors
  1. C L Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V L D Bonato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A A M Coelho-Castelo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A O De Souza
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S A Santos
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K M Lima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L H Faccioli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J M Rodrigues Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Silva, C., Bonato, V., Coelho-Castelo, A. et al. Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice. Gene Ther 12, 281–287 (2005). https://doi.org/10.1038/sj.gt.3302418

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302418

Keywords

This article is cited by

Search

Advanced search

Quick links